FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
美國食品藥品管理局批准了Labcorp的NabCyte抗AAVRH74VAR HB-FE，這是一種用於確定患者是否有資格接受輝瑞最近批准的乙型血友病基因療法Beqvez（Fidanacogene elaparvovec-DZKT）治療的伴隨診斷
FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
美國食品藥品管理局批准了Labcorp的NabCyte抗AAVRH74VAR HB-FE，這是一種用於確定患者是否有資格接受輝瑞最近批准的乙型血友病基因療法Beqvez（Fidanacogene elaparvovec-DZKT）治療的伴隨診斷
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。